Novel therapeutic strategies that target HIF-1 α and other key regulators will limit the capacity for the metabolic rewiring of breast CSCs and render these tumor-initiating cells more vulnerable to the varying conditions of the tumor microenvironment. This evidence concerns the gene SETD2 and neoplasm.